- Trials with a EudraCT protocol (70)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
70 result(s) found for: Optical imaging.
Displaying page 1 of 4.
EudraCT Number: 2005-005592-14 | Sponsor Protocol Number: 26 | Start Date*: 2006-07-27 |
Sponsor Name:IFSgGmbH, Institute for clinical research | ||
Full Title: Double blind, placebo-controlled study to determine the safety and efficacy of erythropoietin as an add-on therapy to methylprednisolone in subjects with acute autoimmune optic neuritis (VISION PRO... | ||
Medical condition: Multiple sclerosis (MS) is a chronic disease of the central nervous system.Optic neuritis represents one of the most common and frequently the first clinical manifestation of MS. Optic neuritis is ... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-000194-93 | Sponsor Protocol Number: ENTRAP | Start Date*: 2021-12-22 |
Sponsor Name:Radboud University Medical Center | ||
Full Title: Exendin PET/CT for imaging of paragangliomas | ||
Medical condition: Paraganglioma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2013-004006-26 | Sponsor Protocol Number: H-4-2013-095 | Start Date*: 2013-12-18 | |||||||||||
Sponsor Name:Knowledge Centre for Rheumatology and Back Diseases | |||||||||||||
Full Title: Optical images for monitoring treatment changes in rheumatoid arthritis – a longitudinal study with Rheumascan | |||||||||||||
Medical condition: Detection of synovitis and tenosynovitis in the hands of patients with rheumatoid arthritis; Diagnostic performance of optical imaging in comparison with ultrasound and magnetic resonance imaging. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002856-26 | Sponsor Protocol Number: ADO-EP02(ML29328) | Start Date*: 2016-12-19 | |||||||||||
Sponsor Name:SRH Wald-Klinikum Gera GmbH | |||||||||||||
Full Title: A PHASE II, SINGLE-ARMED, MULTICENTER TRIAL OF NEOADJUVANT VISMODEGIB IN PATIENTS WITH LARGE AND/OR RECURRENT RESECTABLE BASAL CELL CARCINOMA | |||||||||||||
Medical condition: Patients with large and/or recurrent resectable basal cell carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003022-24 | Sponsor Protocol Number: N19IFC | Start Date*: 2019-10-15 | |||||||||||||||||||||
Sponsor Name:NKI-AVL | |||||||||||||||||||||||
Full Title: INFLUENCE (INtra-operative evaluation of a novel FLUorescENt C-mEt tracer in penile and tongue cancer) | |||||||||||||||||||||||
Medical condition: Penile cancer and tongue cancer | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: NL (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000509-96 | Sponsor Protocol Number: NL71166.041.19 | Start Date*: 2020-05-14 |
Sponsor Name:Princess Maxima Center for pediatric oncology | ||
Full Title: Near-infrared fluorescence imaging using indocyanine green as an adjunct to improve standard-of-care sentinel lymph node procedure in pediatric patients with melanoma or sarcoma of head/neck/trunk,... | ||
Medical condition: Sentinel node procedure for pediatric patients with melanoma or sarcoma | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2011-003775-11 | Sponsor Protocol Number: | Start Date*: 2012-01-12 | |||||||||||||||||||||
Sponsor Name: | |||||||||||||||||||||||
Full Title: Fluoxetine therapy for multiple sclerosis | |||||||||||||||||||||||
Medical condition: progressive multiple sclerosis | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: BE (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-006024-35 | Sponsor Protocol Number: cysteamine gel formulation/07/cysta | Start Date*: 2008-02-04 | |||||||||||
Sponsor Name:Orphan Europe SARL | |||||||||||||
Full Title: Adaptive dose regimen of Cystadrops for cOrneal Crystal deposiTs and ocular manifestations in nephropathic cystinosis : an open label, dose-response pilot study | |||||||||||||
Medical condition: Nephropathic cystinotic patients with cystine crystals corneal deposits | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-005565-40 | Sponsor Protocol Number: OTP-B-Linköping | Start Date*: 2014-09-11 |
Sponsor Name:Department of Biomedical Engineering, Linköping University | ||
Full Title: Optical measurement with 5-ALA during surgical resection of brain tumors in children | ||
Medical condition: Tumour border by means of fluorescenstechnique during surgical resection of brain tumours. | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-001905-66 | Sponsor Protocol Number: BA-SCAD | Start Date*: 2021-07-06 |
Sponsor Name:Spanish Cardiology Society | ||
Full Title: Randomized clinical trial assessing the value of Beta-Blockers and Antiplatelet Agents in patients with Spontaneous Coronary Artery Dissection | ||
Medical condition: Spontaneous Coronary Artery Dissection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2017-001502-15 | Sponsor Protocol Number: 2016-01382 | Start Date*: 2017-12-13 | |||||||||||
Sponsor Name:Insel Gruppe AG - Inselspital | |||||||||||||
Full Title: Effects of the PCSK9 Antibody AliroCuMab on Coronary Atherosclerosis in PatieNts with Acute Myocardial Infarction. A Serial, Multivessel, Intravascular Ultrasound, Near-Infrared Spectroscopy And Op... | |||||||||||||
Medical condition: Patients presenting with acute myocardial infarction (non-ST-elevation myocardial infarction or acute ST-elevation myocardial infarction) and with elevated cholesterol levels. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000519-42 | Sponsor Protocol Number: OPH1008 | Start Date*: 2015-10-26 | ||||||||||||||||
Sponsor Name:OPHTHOTECH CORPORATION | ||||||||||||||||||
Full Title: Role of multimodal imaging in the evaluation of anatomic alterations in neovascular Age-Related Macular Degeneration (AMD) subjects: 18 month Phase 2a open label study of Fovista® (anti-PDGF therap... | ||||||||||||||||||
Medical condition: Subfoveal choroidal neovascularization secondary to Age-Related Macular Degeneration (AMD) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Prematurely Ended) IT (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-002975-25 | Sponsor Protocol Number: 59325 | Start Date*: 2017-11-23 | |||||||||||
Sponsor Name:Bispebjerg Hospital | |||||||||||||
Full Title: Multimodal optical imaging for pretreatment evaluation for cutaneous microparticle delivery | |||||||||||||
Medical condition: Facial acne vulgaris lesions after pretreatment with topical retinoid | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002827-27 | Sponsor Protocol Number: EMI-137-CRC-001 | Start Date*: 2016-12-16 | |||||||||||
Sponsor Name:Edinburgh Molecular Imaging Ltd. | |||||||||||||
Full Title: A Phase IIb, Open Label Study for the Detection of Dysplastic Colorectal Polyps during Colonoscopy after EMI-137 Injection in Patients with High Suspicion of Colorectal Cancer. | |||||||||||||
Medical condition: Dysplastic Colorectal Polyps | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-002500-91 | Sponsor Protocol Number: RPC01-3001 | Start Date*: 2015-10-12 | |||||||||||
Sponsor Name:Celgene International II Sàrl (CIS II) | |||||||||||||
Full Title: A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis | |||||||||||||
Medical condition: Relapsing Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) BE (Completed) GB (Completed) ES (Completed) BG (Completed) SK (Completed) GR (Completed) PL (Completed) LV (Completed) EE (Completed) LT (Completed) PT (Completed) SE (Completed) HR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002503-17 | Sponsor Protocol Number: 20170542 | Start Date*: 2020-08-10 | |||||||||||
Sponsor Name:Amgen Inc | |||||||||||||
Full Title: A Randomized, Double-masked, Phase 3 Study of ABP 938 Efficacy and Safety Compared to Aflibercept (Eylea®) in Subjects with Neovascular Age-related Macular Degeneration | |||||||||||||
Medical condition: Neovascular Age-related Macular Degeneration | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) LV (Completed) EE (Completed) SK (Completed) ES (Ongoing) CZ (Completed) LT (Completed) PL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-003056-36 | Sponsor Protocol Number: CBAF312A2304 | Start Date*: 2012-10-31 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary pro... | |||||||||||||
Medical condition: Secondary progressive multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) IE (Completed) DE (Prematurely Ended) CZ (Completed) SK (Completed) NL (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) AT (Completed) SE (Completed) PT (Prematurely Ended) IT (Prematurely Ended) LV (Completed) GR (Completed) LT (Completed) EE (Completed) BE (Prematurely Ended) PL (Completed) BG (Prematurely Ended) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003578-28 | Sponsor Protocol Number: 2013070001 | Start Date*: 2013-10-21 | |||||||||||
Sponsor Name:Andreas Kjær | |||||||||||||
Full Title: The intraoperative use of fluorescent tracers and multimodal imaging techniques in treatment of head and neck cancer | |||||||||||||
Medical condition: oral cavity cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002531-15 | Sponsor Protocol Number: 09/0959 | Start Date*: 2016-11-14 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:UCL Comprehensive Clinical Trials Unit | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: A phase II, open label, non-randomised, single centre, clinical trial of ANX776 in Healthy Volunteers and patients with Glaucoma, Age-Related Macular Degeneration, and Optic Neuritis | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Glaucoma, Age-related Macular Degeneration, and Optic Neuritis. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: GB (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-000781-38 | Sponsor Protocol Number: sempa1 | Start Date*: 2019-05-07 | |||||||||||
Sponsor Name:Aarhus University Hospital | |||||||||||||
Full Title: Effect of Empagliflozin and Semaglutide on Cardio-Renal Target Organ Damage in patients with type 2 diabetes – A randomized Trial | |||||||||||||
Medical condition: Type 2 Diabetes Mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
